Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype

作者: Brittany Z. Dashevsky , Debra A. Goldman , Molly Parsons , Mithat Gönen , Adriana D. Corben

DOI: 10.1007/S00259-015-3080-Z

关键词:

摘要: To determine if the histology of a breast malignancy influences appearance untreated osseous metastases on FDG PET/CT. This retrospective study was performed under IRB waiver. Our Hospital Information System screened for cancer patients who presented with metastases, underwent PET/CT prior to systemic therapy or radiotherapy from 2009 2012. Patients invasive ductal carcinoma (IDC), lobular (ILC), mixed ductal/lobular (MDL) were included. history other malignancies excluded. evaluated, blinded histology, classify per-patient basis as sclerotic, lytic, lytic/sclerotic, occult CT, and record SUVmax PET. Following screening, 95 met inclusion criteria (74 IDC, 13 ILC, 8 MDL) ILC more commonly sclerotic demonstrated lower than IDC metastases. In all MDL at least one FDG-avid. For lytic FDG-avid metastasis; however, in only three seven apparent The histologic subtype affects particular, non-FDG-avid common IDC. Breast should be considered when interpreting lesions PET/CT, which may suspicious (rather benign lesions) ILC.

参考文章(28)
G J Cook, S Houston, R Rubens, M N Maisey, I Fogelman, Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. Journal of Clinical Oncology. ,vol. 16, pp. 3375- 3379 ,(1998) , 10.1200/JCO.1998.16.10.3375
Norbert Avril, Fritz Jänicke, Jörg Dose, Markus Schwaiger, Marcus Schelling, Walter Nathrath, Wolfgang Weber, Manuela Menzel, Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis The Journal of Nuclear Medicine. ,vol. 42, pp. 9- 16 ,(2001)
N. Avril, C.A. Rosé, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, M. Schwaiger, Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations Journal of Clinical Oncology. ,vol. 18, pp. 3495- 3502 ,(2000) , 10.1200/JCO.2000.18.20.3495
G N Hortobagyi, R L Theriault, A Lipton, L Porter, D Blayney, C Sinoff, H Wheeler, J F Simeone, J J Seaman, R D Knight, M Heffernan, K Mellars, D J Reitsma, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 16, pp. 2038- 2044 ,(1998) , 10.1200/JCO.1998.16.6.2038
Michael Bilous, Patrick Fitzgibbons, Wedad Hanna, Robert B. Jenkins, Pamela B. Mangu, Soonmyung Paik, Edith A. Perez, Michael F. Press, Patricia A. Spears, Gail H. Vance, Giuseppe Viale, Daniel F. Hayes, Antonio C. Wolff, M. Elizabeth H. Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane, Kimberly H. Allison, Donald C. Allred, John M.S. Bartlett, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology & Laboratory Medicine. ,vol. 138, pp. 241- 256 ,(2014) , 10.5858/ARPA.2013-0953-SA
Andreas Buck, Holger Schirrmeister, Thorsten Kühn, Changxian Shen, Thomas Kalker, Jörg Kotzerke, Anja Dankerl, Gerhard Glatting, Sven Reske, Torsten Mattfeldt, FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 29, pp. 1317- 1323 ,(2002) , 10.1007/S00259-002-0880-8
Ora Israel, Anat Goldberg, Alicia Nachtigal, Daniela Militianu, Rachel Bar-Shalom, Zohar Keidar, Ignac Fogelman, FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 33, pp. 1280- 1284 ,(2006) , 10.1007/S00259-006-0141-3
Gary A. Ulaner, Anne Eaton, Patrick G. Morris, Joshua Lilienstein, Komal Jhaveri, Sujata Patil, Maurizio Fazio, Steven Larson, Clifford A. Hudis, Maxine S. Jochelson, Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Medicine. ,vol. 2, pp. 725- 733 ,(2013) , 10.1002/CAM4.119
A. Caldarella, C. Buzzoni, E. Crocetti, S. Bianchi, V. Vezzosi, P. Apicella, M. Biancalani, A. Giannini, C. Urso, F. Zolfanelli, E. Paci, Invasive breast cancer: a significant correlation between histological types and molecular subgroups Journal of Cancer Research and Clinical Oncology. ,vol. 139, pp. 617- 623 ,(2013) , 10.1007/S00432-012-1365-1
Wendie A. Berg, Lorena Gutierrez, Moriel S. NessAiver, W. Bradford Carter, Mythreyi Bhargavan, Rebecca S. Lewis, Olga B. Ioffe, Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. ,vol. 233, pp. 830- 849 ,(2004) , 10.1148/RADIOL.2333031484